头颈癌中人类白细胞抗原缺失与免疫逃逸
本研究为横断面整合临床与基因组分析,对癌症基因组图谱头颈鳞癌队列522例肿瘤的全外显子组和RNA测序数据及免疫细胞解卷积数据进行分析,发现53%的头颈鳞癌肿瘤存在HLA杂合性缺失(LOH),且与晚期肿瘤和淋巴细胞及T细胞浸润减少的冷免疫微环境相关。
要点
- 53%的头颈鳞癌肿瘤中检测到HLA LOH,为常见遗传学事件。
- HLA LOH在晚期肿瘤中更常见,且与淋巴细胞和T细胞浸润减少相关。
- HLA LOH可能作为预测性生物标志物或癌细胞特异性治疗靶点。
核心结论
- HLA LOH是头颈鳞癌中最常见的遗传学改变之一,与冷免疫微环境相关,提示HLA LOH是一种免疫逃逸机制,可能具有预测性生物标志物价值或作为癌细胞特异性治疗靶点的潜力。
研究设计与样本
- 横断面整合临床与基因组分析,分析癌症基因组图谱头颈鳞癌队列中522例肿瘤的全外显子组测序和RNA测序数据,并与免疫细胞解卷积数据等二次分析整合。
主要发现
- HLA LOH在53%的头颈鳞癌肿瘤中被检测到;许多病例中不止一个I类HLA基因发生LOH。
- HLA LOH在晚期肿瘤中更常见。
- 伴有体细胞HLA LOH的肿瘤其微环境表现为淋巴细胞和T细胞浸润减少。
临床怎么用
- 作者认为HLA LOH可能具有预测性生物标志物价值或作为癌细胞特异性治疗靶点的潜力。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES/HYPOTHESIS: Cancer cells evade recognition by the immune system to survive. Head and neck squamous cell carcinoma (HNSCC) is characterized by high levels of immune infiltration and mutation-associated neoantigens; therefore, immune evasion is likely to be an important mechanism in HNSCC tumorigenesis and progression. A commonly employed mechanism of immune evasion is downregulation of human leukocyte antigen (HLA) or loss of heterozygosity (LOH) in tumor cells. The objective of this study was to integrate multi-dimensional genomic and transcriptomic data from HNSCC tumors to better understand the clinical and immunologic implications of HLA LOH. STUDY TYPE/DESIGN: Cross-sectional integrated clinical and genomic analysis. METHODS: Whole-exome sequencing and RNA-sequencing data from 522 tumors profiled in The Cancer Genome Atlas HNSCC cohort were analyzed and integrated with secondary analyses including immune cell deconvolution data. Associations were analyzed with categorical hypothesis testing and multivariable logistic and Cox regression. RESULTS: HLA LOH was a prevalent event that was identified in 53% of HNSCC tumors; in many cases, more than one class I HLA gene was targeted for LOH. HLA LOH was more common in advanced-stage tumors. Tumors with somatic HLA LOH had tumor microenvironments defined by decreased lymphocyte and T cell infiltration. CONCLUSIONS: HLA LOH is one of the most prevalent genetic alterations in HNSCC, and is associated with a cold immune microenvironment, suggesting that HLA LOH is a means of immune evasion. It may have value as a predictive biomarker or potential as a cancer cell-specific therapeutic target. LEVEL OF EVIDENCE: 3 Laryngoscope, 134:160-165, 2024.
引用
- Morris LGT. Loss of Human Leukocyte Antigen and Immune Escape in Head and Neck Cancer. Laryngoscope. 2023. PMID: 37249223. doi:10.1002/lary.30761
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。